Publications by authors named "Andrea Seitzinger"

Claim this Profile
E
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Andrea Seitzinger

Mult Scler· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a analysis.
Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Andrea Seitzinger

Ther Adv Neurol Disord· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
Johan L van der Plas, Vincent P Kuiper, Wilhelmina M Bagchus, Matthias Bödding, Özkan Yalkinoglu, Andrea Seitzinger

Lancet Infect Dis· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Amit Bar-Or, Anne H Cross, Anthony L Cunningham, Yann Hyvert, Andrea Seitzinger

Mult Scler· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Francesco Piras, Lilian Arnaud, Eric Henninger, Matthew Keiser, Andrea Seitzinger

Expert Opin Drug Deliv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Marco Battaglini, Hugo Vrenken, Riccardo Tappa Brocci, Giordano Gentile, Ludovico Luchetti, Andrea Seitzinger

Eur J Neurol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis.
Mark S Freedman, Dominic Jack, Zuzana Murgašová, Milorad Todorović, Andrea Seitzinger

Mult Scler Relat Disord· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.
Dirk Dressler, Sebastian Paus, Andrea Seitzinger, Bernd Gebhardt, Andreas Kupsch

J Neurol Neurosurg Psychiatry· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis